Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP55360.RAqiB6t52EuxJOLtuX7SugaGy2Nj7YjwfbYUvHV_0RKms130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP55360.RAqiB6t52EuxJOLtuX7SugaGy2Nj7YjwfbYUvHV_0RKms130_provenance.
• NP52811.RAwERWhPUkwANh1Lm5nSOe7xB_7PTETL673ZfLSbrzZb0130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP52811.RAwERWhPUkwANh1Lm5nSOe7xB_7PTETL673ZfLSbrzZb0130_provenance.
• NP64345.RA6dOpzI1qvCZP1Y6KdjKBglLkR2OUHy6gN40nZlwXpIo130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP64345.RA6dOpzI1qvCZP1Y6KdjKBglLkR2OUHy6gN40nZlwXpIo130_provenance.
• NP67526.RA6c2e_OvsVpC8eLwbU6Ox0Wox5ULLKTICRYBhtYjl9J4130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP67526.RA6c2e_OvsVpC8eLwbU6Ox0Wox5ULLKTICRYBhtYjl9J4130_provenance.
• NP65887.RANR7GUO1OXriwOx6lkcGgFMfDjCFgCDbozZ9OcVbiUYw130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP65887.RANR7GUO1OXriwOx6lkcGgFMfDjCFgCDbozZ9OcVbiUYw130_provenance.
• assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP85167.RAQIlYFEY85dV-ed77jfW_VzOyB3TJgb5DfEC_ksJrE-A130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP85167.RAQIlYFEY85dV-ed77jfW_VzOyB3TJgb5DfEC_ksJrE-A130_provenance.
• assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP98437.RATLaJK1cMOferBQdezwpUFTAe7j5pPz1FAZuq18GWRug130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP98437.RATLaJK1cMOferBQdezwpUFTAe7j5pPz1FAZuq18GWRug130_provenance.
• NP98441.RATyL6yMh-OPvnQkpo7uOgiwVOw6dIExBp1phjvVic3V0130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP98441.RATyL6yMh-OPvnQkpo7uOgiwVOw6dIExBp1phjvVic3V0130_provenance.
• NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_provenance.
• NP69784.RAgOtblauTM8rhk2MxRvYRJFIjmj6YV6JtmOJQnIGI51U130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP69784.RAgOtblauTM8rhk2MxRvYRJFIjmj6YV6JtmOJQnIGI51U130_provenance.
• NP87103.RAh3H3K33v6NWQnmpCw6S8xz0X6VTE1E63zxmbMPcDNws130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP87103.RAh3H3K33v6NWQnmpCw6S8xz0X6VTE1E63zxmbMPcDNws130_provenance.
• assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP76420.RACq_Rm1TOqUQNPuKeErl14Q3sB4F4FFhtaY3CMcSVgfk130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP76420.RACq_Rm1TOqUQNPuKeErl14Q3sB4F4FFhtaY3CMcSVgfk130_provenance.
• NP98435.RADSc9hMX_pJtWmgb1xmtRCdL6OcJNLOpwHzfELzqRus8130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP98435.RADSc9hMX_pJtWmgb1xmtRCdL6OcJNLOpwHzfELzqRus8130_provenance.
• NP98438.RApQK6rSnbGbem9eSPhM-zF3sj121w2AiIynv7Wd-FYvQ130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP98438.RApQK6rSnbGbem9eSPhM-zF3sj121w2AiIynv7Wd-FYvQ130_provenance.
• NP98442.RAsAR7k-QCqlhZmfjGJGPmq6dcJMJEF1jpi4gQrjDB-8I130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP98442.RAsAR7k-QCqlhZmfjGJGPmq6dcJMJEF1jpi4gQrjDB-8I130_provenance.
• NP65627.RA9zWUkHH5cE5lxdx36lz5oMUGzfoLFJIkCQIuWpBv5Jg130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP65627.RA9zWUkHH5cE5lxdx36lz5oMUGzfoLFJIkCQIuWpBv5Jg130_provenance.
• NP79229.RAzR-ZMsS1iskJHIl1Gfcl6Oxn1PoNJiK560IaUqjhmyo130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP79229.RAzR-ZMsS1iskJHIl1Gfcl6Oxn1PoNJiK560IaUqjhmyo130_provenance.
• NP83378.RA27vZEHmgtB1x9ElL6X4B_JLcf0_DMhSL7YVRkjP8NeI130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP83378.RA27vZEHmgtB1x9ElL6X4B_JLcf0_DMhSL7YVRkjP8NeI130_provenance.
• NP98436.RAGPWMgFq35-KQJrG_iBbewmN5soNzhZfIIQzXlaHTiQI130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP98436.RAGPWMgFq35-KQJrG_iBbewmN5soNzhZfIIQzXlaHTiQI130_provenance.
• NP98439.RAEH2av85BTHUglLTLlmxvXNd-iRAl1Q6OXtJMRH_tIQQ130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP98439.RAEH2av85BTHUglLTLlmxvXNd-iRAl1Q6OXtJMRH_tIQQ130_provenance.
• NP98440.RAEOFLCn9X7_LRFczWclQVfFdrXx5T_lC_AVxgaTW7h7Q130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP98440.RAEOFLCn9X7_LRFczWclQVfFdrXx5T_lC_AVxgaTW7h7Q130_provenance.